(Q34549410)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

International uniform response criteria for multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

Erratum: International uniform response criteria for multiple myeloma

27 December 2019

corrigendum / erratum

Erratum: International uniform response criteria for multiple myeloma

1

0 references

2

0 references

author

Athanasios Dimopoulos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Giampaolo Merlini

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Gareth J Morgan

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

S. Vincent Rajkumar

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

7

M Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1

B G M Durie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

J-L Harousseau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

J S Miguel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

J Bladé

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

B Barlogie

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

K Anderson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

J Westin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

P Sonneveld

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

H Ludwig

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

G Gahrton

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

M Beksac

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

J Crowley

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

A Belch

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

M Boccadaro

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

M Cavo

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

I Turesson

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

D Joshua

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

D Vesole

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

R Kyle

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

R Alexanian

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

G Tricot

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

M Attal

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

R Powles

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

P Richardson

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

K Shimizu

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

P Tosi

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

International Myeloma Working Group

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

20 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

1467-1473

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404284

27 December 2019

exact match

0 references

cites work

New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

POEMS syndrome: definitions and long-term outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Serum test for assessment of patients with Bence Jones myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Serum free light chains for monitoring multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Is magnitude of initial response predictive for survival in multiple myeloma?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404284

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404284

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855634%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 December 2019

0 references

1 reference